Osivax Partners with CEPI to Advance T-cell Immunity using World-First Adjuvant Library Access to CEPI’s Adjuvant Library to assess dose-sparing potential of adjuvanted formulations of OVX836 vaccine in flu pandemic settings Potential to maximize vaccine supply and broaden global access in emergencies, while maintaining a non-adjuvanted OVX836 core development path Lyon, France and Liège, Belgium – …
Tag archives: OVX836
Osivax Completes Enrollment in Phase 2b Asuniva Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate OVX836
Osivax Completes Enrollment in Phase 2b Asuniva Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate OVX836 Target enrollment of 2,850 healthy volunteers completed across multiple European countries Topline data read-out expected by mid-2026, subject to influenza circulation during the winter season Lyon, France and Liège, Belgium – December 09, 2025 – Osivax, a biopharmaceutical company developing …
Osivax Announces First Participant Vaccinated in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate, OVX836
Osivax Announces First Participant Vaccinated in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate, OVX836 Phase 2b to assess efficacy, safety, and immunogenicity 2,850 participants to be enrolled across European countries Lyon, France and Liège, Belgium – September 16, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating …
Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness
Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness Funding to accelerate development of Osivax’ broad-spectrum influenza A vaccine candidate, OVX836 Lyon, France and Liège, Belgium – August 26, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced it has …
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profile Robust complementary immune responses were induced, with no major interference observed Lyon, France – July 10, 2025 – Osivax, a biopharmaceutical company …
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 Final results expected in H2 2025 Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that all participants have completed their final visit …
I4ID 2024
Lyon, France – PosterSéverine Valsesia, Immuno R&D engineer, to present a poster entitled “A mix of OVX836, a NP-based influenza vaccine candidate, with a commercial seasonal vaccine is immunogenic and synergistically protective in mice”. François Fasquelle, Clinical Immunology Project Manager, to present a poster entitled “OVX836, a NP-based broad-spectrum influenza vaccine candidate, is safe, immunogenic …
World Vaccines Congress Europe 2024
Barcelona, Spain – Oral PresentationNicola Groth, Chief Medical Officer, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Update of OVX836, a Novel Broad-Spectrum Type A Influenza Vaccine Candidate”.
Influenza Vaccines for the World 2024
Siena, Italy – Oral PresentationNicola Groth, Chief Medical Officer of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical development update on OVX836, a T-cell based broad-spectrum influenza vaccine”.
World Congress Vaccine Washington 2024
Washington, DC – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical development update on OVX836, a T-cell based broad-spectrum influenza vaccine”.